Online First Nr75

Psychiatr. Pol. ONLINE FIRST Nr 75 1–11

Published ahead of print 14 August 2017


Fakher Rahim, Mehdi Sayyah

Wpływ atorwastatyny na leczenie lekoopornych zaburzeń obsesyjno kompulsyjnych: badanie przeprowadzone metodą podwójnie ślepej próby z randomizacją

Effects of atorvastatin on treatment-resistant obsessive-compulsive disorder: A double-blind randomized trial

Objective. Obsessive-compulsive disorder (OCD) is a chronic disorder of unknown etiology. An augmentation strategy is an approach for treatment-resistant OCD. This study was planned to assess the effect of atorvastatin on treatment-resistant OCD.
Methods. This 12-week-long double-blind randomized trial was performed on 26 adult patients with treatment-resistant OCD. They were diagnosed with this kind of disorder based on the DSM-IV-TR. The patients were randomized to receive either 10 mg/day atorvastatin or placebo. The Yale-Brown scale was assessed at the baseline and 12 weeks later.
Results. There were significant reductions in the obsession subtotal score of the Y-BOCS (p = 0.017) and the total Y-BOCS score (p = 0.041) in the atorvastatin group. Hence, the reduction in the Y-BOCS compulsive score (p = 0.081) was not statistically significant. Atorvastatin was generally well tolerated. There was a significant reduction in libido in the atorvastatin group (p = 0.019).
Conclusions. The results of this study should be interpreted in the shadow of its restrictions. Some of the restrictions were a limited number of patients in the trial, a 12-week-long time trial, and not measuring NO before and after the study. It is recommended that researchers should consider these items in similar type of studies.

ISSN 0033-2674 (PRINT)

ISSN 2391-5854 (ONLINE)

Inne strony PTP:
Other PTP websites:

Psychiatria Polska
Thomson Reuters Master List
Science Citation Index Expanded
Journal Citation Reports
(Impact Factor 1,010)

Medline/Index Medicus
MNiSW (15 pkt)
EMBASE/Excerpta Medica
Index Copernicus (18.59)
Erih Plus, Cochrane Library

Psychiatria Polska
is an open access journal

We recommend:
Pharmacological Reports

+48  518-330-994
kontakt z Biurem KRW PTP